Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3513193 | 0.81 | BTK (0.32) | IKBKB | |
| SCHEMBL3511495 | 0.80 | ALDH1A1 (0.39) | — | |
| SCHEMBL3514868 | 0.77 | PIK3CA (0.32) | PIK3CAPIK3CB | |
| SCHEMBL3512953 | 0.76 | PIK3CD (0.31) | PIK3CDPIK3CA | |
| SCHEMBL3514552 | 0.76 | PIK3CA (0.32) | PIK3CAPIK3CB | |
| SCHEMBL3512226 | 0.76 | PIK3CD (0.36) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3510853 | 0.76 | BTK (0.47) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2703536 | 0.75 | PIK3CA (0.35) | PIK3CDPIK3CAPIK3CBPIK3CGPI4KB | |
| SCHEMBL5519898 | 0.75 | CNR1 (0.49) | CNR1CNR2IKBKB | |
| SCHEMBL3513647 | 0.75 | CCNA2 (0.39) | PI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| EP-2240475-B1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-20100298286-A1 | Organic Compounds | NOVARTIS AG | 2010-11-25 | — | — | US | disclosed |
| EP-2240475-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | Novartis AG (CH) | 2010-10-20 | — | — | EP | disclosed |
| EP-2238134-A2 | BIS-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009080694-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080705-A2 | BIS-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298286-A1 | Organic Compounds | PIK3CA, PI4KB, PIK3CB | CNR1 2031/4885CNR2 2088/4885IKBKB 190/4885 |
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | CNR1 4068/4885CNR2 4058/4885IKBKB 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.